Western equine encephalitis virus structural polyprotein (WEEV structural protein)

The Western equine encephalitis virus (WEEV) structural polyprotein is a critical precursor molecule that is processed into the individual proteins required for viral assembly and infection: Capsid (C), E3, E2, 6K, and E1 (UniProt: P13896). These proteins collectively form the icosahedral nucleocapsid and the lipid envelope of the virion. The E2 glycoprotein is primarily responsible for attachment to host cell receptors, while E1 facilitates the pH-dependent fusion of the viral and host membranes within endosomes (PubMed: 25653431). As the most exposed components of the virus, these structural proteins are the primary targets for neutralizing antibodies and are central to the development of vaccines and therapeutic interventions (PubMed: 17159131). WEEV is a member of the Alphavirus genus and is a significant cause of zoonotic encephalitis in North America, making its structural proteins vital targets for public health preparedness. Current research focuses on using these proteins in DNA vaccines, recombinant subunits, and as targets for neutralizing monoclonal antibodies to provide protection against aerosol and mosquito-borne exposure (PubMed: 24109232).

Other names

WEEV structural proteinWEEV polyproteinCapsid protein CEnvelope glycoprotein E2Envelope glycoprotein E16K proteinE3 protein

The primary mechanism involves the neutralization of viral infectivity by binding to the E2 or E1 glycoproteins, thereby preventing host cell attachment or inhibiting the pH-triggered conformational changes required for membrane fusion (PubMed: 25653431). Vaccines targeting these proteins aim to elicit long-lasting neutralizing antibody titers and T-cell responses to prevent systemic infection and neuroinvasion (PubMed: 17159131).